Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Masanori Kobayashi, Tomoyo Sakabe, Hirofumi Abe, Mitsugu Tanii, Hidenori Takahashi, Asako Chiba, Eri Yanagida, Yuta Shibamoto, Masahiro Ogasawara, Shun ichi Tsujitani, Shigeo Koido, Kazuhiro Nagai, Shigetaka Shimodaira, Masato Okamoto, Yoshikazu Yonemitsu, Noboru Suzuki, Masaki Nagaya

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023). Conclusions: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.

Original languageEnglish
Pages (from-to)1609-1617
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

Biliary Tract Neoplasms
Immunotherapy
Dendritic Cells
Vaccination
Peptides
Wilms Tumor
Drug Therapy
Survival
Mucin-1
Nutrition Assessment
Nutritional Status
C-Reactive Protein
Albumins
Fever
Retrospective Studies
Safety

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Kobayashi, M., Sakabe, T., Abe, H., Tanii, M., Takahashi, H., Chiba, A., ... Nagaya, M. (2013). Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer. Journal of Gastrointestinal Surgery, 17(9), 1609-1617. https://doi.org/10.1007/s11605-013-2286-2

Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer. / Kobayashi, Masanori; Sakabe, Tomoyo; Abe, Hirofumi; Tanii, Mitsugu; Takahashi, Hidenori; Chiba, Asako; Yanagida, Eri; Shibamoto, Yuta; Ogasawara, Masahiro; Tsujitani, Shun ichi; Koido, Shigeo; Nagai, Kazuhiro; Shimodaira, Shigetaka; Okamoto, Masato; Yonemitsu, Yoshikazu; Suzuki, Noboru; Nagaya, Masaki.

In: Journal of Gastrointestinal Surgery, Vol. 17, No. 9, 01.09.2013, p. 1609-1617.

Research output: Contribution to journalArticle

Kobayashi, M, Sakabe, T, Abe, H, Tanii, M, Takahashi, H, Chiba, A, Yanagida, E, Shibamoto, Y, Ogasawara, M, Tsujitani, SI, Koido, S, Nagai, K, Shimodaira, S, Okamoto, M, Yonemitsu, Y, Suzuki, N & Nagaya, M 2013, 'Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer', Journal of Gastrointestinal Surgery, vol. 17, no. 9, pp. 1609-1617. https://doi.org/10.1007/s11605-013-2286-2
Kobayashi, Masanori ; Sakabe, Tomoyo ; Abe, Hirofumi ; Tanii, Mitsugu ; Takahashi, Hidenori ; Chiba, Asako ; Yanagida, Eri ; Shibamoto, Yuta ; Ogasawara, Masahiro ; Tsujitani, Shun ichi ; Koido, Shigeo ; Nagai, Kazuhiro ; Shimodaira, Shigetaka ; Okamoto, Masato ; Yonemitsu, Yoshikazu ; Suzuki, Noboru ; Nagaya, Masaki. / Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer. In: Journal of Gastrointestinal Surgery. 2013 ; Vol. 17, No. 9. pp. 1609-1617.
@article{2b69d2006a3949b49d6c57af1615f5b7,
title = "Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer",
abstract = "Background: The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023). Conclusions: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.",
author = "Masanori Kobayashi and Tomoyo Sakabe and Hirofumi Abe and Mitsugu Tanii and Hidenori Takahashi and Asako Chiba and Eri Yanagida and Yuta Shibamoto and Masahiro Ogasawara and Tsujitani, {Shun ichi} and Shigeo Koido and Kazuhiro Nagai and Shigetaka Shimodaira and Masato Okamoto and Yoshikazu Yonemitsu and Noboru Suzuki and Masaki Nagaya",
year = "2013",
month = "9",
day = "1",
doi = "10.1007/s11605-013-2286-2",
language = "English",
volume = "17",
pages = "1609--1617",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

AU - Kobayashi, Masanori

AU - Sakabe, Tomoyo

AU - Abe, Hirofumi

AU - Tanii, Mitsugu

AU - Takahashi, Hidenori

AU - Chiba, Asako

AU - Yanagida, Eri

AU - Shibamoto, Yuta

AU - Ogasawara, Masahiro

AU - Tsujitani, Shun ichi

AU - Koido, Shigeo

AU - Nagai, Kazuhiro

AU - Shimodaira, Shigetaka

AU - Okamoto, Masato

AU - Yonemitsu, Yoshikazu

AU - Suzuki, Noboru

AU - Nagaya, Masaki

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023). Conclusions: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.

AB - Background: The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023). Conclusions: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.

UR - http://www.scopus.com/inward/record.url?scp=84883222978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883222978&partnerID=8YFLogxK

U2 - 10.1007/s11605-013-2286-2

DO - 10.1007/s11605-013-2286-2

M3 - Article

VL - 17

SP - 1609

EP - 1617

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 9

ER -